Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RNANASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$25.76-3.4%$29.80$21.51▼$56.00$3.10B1.011.40 million shs1.56 million shsSRPTSarepta Therapeutics$53.94-0.9%$84.51$48.01▼$173.25$5.23B0.931.40 million shs1.44 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences-3.45%+3.87%-23.85%-8.94%+7.74%SRPTSarepta Therapeutics-0.88%-3.07%-46.78%-53.92%-54.01%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRNAAvidity Biosciences2.1072 of 5 stars4.50.00.00.03.30.80.0SRPTSarepta Therapeutics4.6719 of 5 stars4.42.00.04.22.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRNAAvidity Biosciences 3.00Buy$66.69158.90% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$161.83200.01% UpsideCurrent Analyst Ratings BreakdownLatest RNA and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$75.00 ➝ $75.004/11/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$196.00 ➝ $182.004/11/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$115.004/9/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/3/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$202.00 ➝ $183.004/2/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$75.00 ➝ $75.003/31/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$161.00 ➝ $87.003/20/2025SRPTSarepta TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$105.00 ➝ $80.003/19/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$124.00 ➝ $99.003/19/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$75.00 ➝ $75.003/18/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.00 ➝ $202.00(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRNAAvidity Biosciences$10.90M284.18N/AN/A$6.76 per share3.81SRPTSarepta Therapeutics$1.90B2.75N/AN/A$9.19 per share5.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRNAAvidity Biosciences-$212.22M-$2.89N/AN/AN/A-2,772.45%-27.66%-24.56%5/8/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M$2.2843.154.93N/A7.43%11.00%3.35%4/29/2025 (Estimated)Latest RNA and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RNAAvidity Biosciences-$0.88N/AN/AN/A$2.63 millionN/A5/7/2025Q1 2025SRPTSarepta Therapeutics$2.20N/AN/AN/A$685.75 millionN/A2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRNAAvidity BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRNAAvidity BiosciencesN/A17.7617.76SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRNAAvidity BiosciencesN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRNAAvidity Biosciences3.68%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRNAAvidity Biosciences190120.21 million114.92 millionOptionableSRPTSarepta Therapeutics84097.03 million88.17 millionOptionableRNA and SRPT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 16 at 1:30 PM | accessnewswire.comSarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory AdvancementsApril 16 at 9:10 AM | tipranks.comSRPT Provides Pipeline Updates on Rare Muscular Disorder TherapiesApril 16 at 8:35 AM | zacks.comCautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS UncertaintiesApril 16 at 6:40 AM | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 15 at 2:30 PM | accessnewswire.comSarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy ProgramsApril 15 at 8:30 AM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 14 at 6:19 PM | prnewswire.comF M Investments LLC Acquires Shares of 16,924 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)April 14 at 5:41 AM | marketbeat.comBank of Nova Scotia Sells 185,102 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)April 14 at 5:13 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $163.18 Consensus Price Target from AnalystsApril 14 at 2:53 AM | americanbankingnews.comWells Fargo & Company Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)April 14 at 1:45 AM | americanbankingnews.comMorgan Stanley Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00April 14 at 1:45 AM | americanbankingnews.comMorgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00April 13, 2025 | marketbeat.comWells Fargo & Company Begins Coverage on Sarepta Therapeutics (NASDAQ:SRPT)April 13, 2025 | marketbeat.comCapital Fund Management S.A. Has $21.13 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)April 13, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Moderate Buy" by BrokeragesApril 13, 2025 | marketbeat.comSRPT Investigation: Kessler Topaz Meltzer & Check,April 12, 2025 | kxan.comSRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. ...April 12, 2025 | gurufocus.comSarepta Therapeutics Inc (SRPT) Under Investigation for Potential Securities Law Violations | ...April 12, 2025 | gurufocus.comSarepta Therapeutics Inc (SRPT) Under Investigation for Potential Securities Law Violations | ...April 12, 2025 | gurufocus.comSRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the FirmApril 12, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNA and SRPT Company DescriptionsAvidity Biosciences NASDAQ:RNA$25.76 -0.92 (-3.45%) As of 04/16/2025 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$53.94 -0.48 (-0.88%) As of 04/16/2025 04:00 PM EasternSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
